Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/51140
Type
ArticleCopyright
Open access
Collections
- IOC - Artigos de Periódicos [12507]
Metadata
Show full item record
GISAID’S ROLE IN PANDEMIC RESPONSE
Author
Affilliation
GISAID Global Data Science Initiative. Munich, Germany / Bioinformatics Institute. Agency for Science Technology and Research. Singapore.
GISAID Global Data Science Initiative. Munich, Germany.
GISAID Global Data Science Initiative. Munich, Germany / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
GISAID Global Data Science Initiative. Munich, Germany.
GISAID Global Data Science Initiative. Munich, Germany.
GISAID Global Data Science Initiative. Munich, Germany / Institut Pasteur de Dakar. Dakar, Senegal.
GISAID Global Data Science Initiative. Munich, Germany.
GISAID Global Data Science Initiative. Munich, Germany / Bioinformatics Institute. Agency for Science Technology and Research. Singapore.
GISAID Global Data Science Initiative. Munich, Germany / Bioinformatics Institute. Agency for Science Technology and Research. Singapore.
GISAID Global Data Science Initiative. Munich, Germany / Bioinformatics Institute. Agency for Science Technology and Research. Singapore.
GISAID Global Data Science Initiative. Munich, Germany / Bioinformatics Institute. Agency for Science Technology and Research. Singapore / Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Rio de Janeiro, RJ, Brazil / National Institutes of Biotechnology Malaysia, Selangor, Malaysia / Smorodintsev Research Institute of Influenza. St. Petersburg, Russia / Genome Institute of Singapore. Agency for Science Technology and Research. Singapore / China National GeneBank. Shenzhen, China.
GISAID Global Data Science Initiative. Munich, Germany / Bioinformatics Institute. Agency for Science Technology and Research. Singapore / A*STAR Infectious Disease Labs (ID Labs). Singapore / National Public Health Laboratory, National Centre for Infectious Diseases. Ministry of Health. Singapore / Department of Biological Sciences. National University of Singapore. Singapore.
GISAID Global Data Science Initiative. Munich, Germany.
GISAID Global Data Science Initiative. Munich, Germany / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
GISAID Global Data Science Initiative. Munich, Germany.
GISAID Global Data Science Initiative. Munich, Germany.
GISAID Global Data Science Initiative. Munich, Germany / Institut Pasteur de Dakar. Dakar, Senegal.
GISAID Global Data Science Initiative. Munich, Germany.
GISAID Global Data Science Initiative. Munich, Germany / Bioinformatics Institute. Agency for Science Technology and Research. Singapore.
GISAID Global Data Science Initiative. Munich, Germany / Bioinformatics Institute. Agency for Science Technology and Research. Singapore.
GISAID Global Data Science Initiative. Munich, Germany / Bioinformatics Institute. Agency for Science Technology and Research. Singapore.
GISAID Global Data Science Initiative. Munich, Germany / Bioinformatics Institute. Agency for Science Technology and Research. Singapore / Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Rio de Janeiro, RJ, Brazil / National Institutes of Biotechnology Malaysia, Selangor, Malaysia / Smorodintsev Research Institute of Influenza. St. Petersburg, Russia / Genome Institute of Singapore. Agency for Science Technology and Research. Singapore / China National GeneBank. Shenzhen, China.
GISAID Global Data Science Initiative. Munich, Germany / Bioinformatics Institute. Agency for Science Technology and Research. Singapore / A*STAR Infectious Disease Labs (ID Labs). Singapore / National Public Health Laboratory, National Centre for Infectious Diseases. Ministry of Health. Singapore / Department of Biological Sciences. National University of Singapore. Singapore.
Abstract
GISAID is a global data science initiative and the
primary source of genomic and associated metadata of
all influenza viruses, Respiratory Syncytial Virus (RSV)
and severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), the pandemic coronavirus causing
coronavirus disease 2019 (COVID-19). GISAID’s
publicly accessible data sharing platform enables
collaboration of over 42,000 participating researchers
from 198 nations and data generators from over 3,500
institutions across the globe. Since the first wholegenome
sequences were made available by China CDC
through GISAID on January 10, 2020, over 5 million
genetic sequences of SARS-CoV-2 from 194 countries
and territories have been made publicly available
through GISAID’s EpiCoV database as of November
9, 2021. This high-quality, curated data enabled the
rapid development of diagnostic and prophylactic
measures against SARS-CoV-2 including the first
diagnostic tests and the first vaccines to combat
COVID-19 as well as continuous monitoring of
emerging variants in near real-time.
Share